Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The primary objectives of this study are to are to compare the SVR12 rates (12-week sustained virologic response, SVR12 [HCV RNA < LLOQ 12 weeks following therapy]) of 8 or 12 weeks of treatment with ABT-493/ABT-530 combination in HCV genotype 1 – 6 infected subjects with HIV-1 co-infection to a pre-defined threshold, based on the historical SVR12 rate of the current standard of care (i.e., sofosbuvir/ledipasvir for 12 weeks or grazoprevir/elbasvir for 12 weeks) and to assess the safety of treatment with the combination regimen ABT-493/ABT-530 for 8 or 12 weeks in HCV genotype 1 – 6 infected subjects with HIV-1 co-infection.
Critère d'inclusion
- Hepatitis C Virus Infection
- Human Immunodeficiency Virus Infection
- Chronic Hepatitis C
- Compensated Cirrhosis and Non-cirrhotics